AXQ Capital’s Regenxbio RGNX Stock Holding History

AXQ Capital’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-13,732	Closed	-$106K	–	659
2024 Q4	$106K	Buy	+13,732	New	+$129K	0.05%	376

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

AXQ Capital's RGNX Position: Q1 2025 in Review

AXQ Capital sold out of Regenxbio (RGNX) in Q1 2025, closing a stake of 13,732 shares — an estimated $106K sold.

AXQ Capital first reported a position in RGNX in Q4 2024 and held it in 1 quarter. The position peaked at $106K in Q4 2024. 164 funds tracked by Wall St. Rank hold RGNX as of Q1 2025.

AXQ Capital reported no remaining Regenxbio position as of Q1 2025 after selling out during the quarter.
AXQ Capital sold 13,732 Regenxbio shares in Q1 2025, an estimated $106K.
AXQ Capital first reported a position in Regenxbio in Q4 2024 and held it in 1 quarter.
AXQ Capital's Regenxbio position peaked at $106K in Q4 2024.
164 funds tracked by Wall St. Rank held Regenxbio as of Q1 2025.

Based on AXQ Capital's 13F filing for Q1 2025, filed 13 May 2025.